SCHEMBL24702149

SCHEMBL24702149

CC(C)OCCOc1cccnn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.34
GRM4 Q14833 2/20 0.33
TSHR P16473 3/20 0.33
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 2/20 0.33
CYP2C9 P11712 2/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
POLB P06746 2/20 0.32
CTDSP1 Q9GZU7 1/20 0.32
MEN1 O00255 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10203008 0.81 GABRP (0.41) MAPK1HTTMEN1KMT2A
SCHEMBL23975682 0.80 TSHR (0.39) TSHRALDH1A1LMNAHSD17B10CYP1A2
SCHEMBL10203014 0.79 PPIA (0.39) HPGDHTTPOLBMEN1KMT2A
SCHEMBL16511359 0.79 TSHR (0.43) HPGDGRM4TSHRALDH1A1KDM4E
SCHEMBL4276013 0.78 NPC1 (0.39) HPGDALDH1A1KDM4ECYP2C9LMNA
SCHEMBL27961066 0.78 CTDSP1 (0.32) CTDSP1RXRAGRIN1GRIN2BHDAC1
SCHEMBL13139432 0.77 NCF1 (0.38) HPGDGRM4TSHRALDH1A1KDM4E
SCHEMBL4272287 0.77 CYP2D6 (0.44) TSHRALDH1A1KDM4ECYP2C9LMNA
SCHEMBL24702303 0.76 NPY5R (0.36) GRM4TSHRHDAC1HDAC6HDAC5
SCHEMBL898231 0.75 SOAT1 (0.44) TSHRCYP2C9LMNASMN1; SMN2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2022-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI HPGD 245/4885GRM4 4849/4885TSHR 2165/4885
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS HAMP, SLC40A1, FANCI HPGD 245/4885GRM4 4849/4885TSHR 2165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.